LETTERS

Radiological sign of a long line in the ascending lumbar vein

We would like to draw attention to a useful radiological sign indicating that a percutaneous central venous catheter may be in the ascending lumbar vein. In our neonatal unit there have been two confirmed cases where the ascending lumbar vein had inadvertently been cannulated. In both these cases a loop in the line had been noted in the region of the ileo-femoral vein (see figs 1 and 2). This “looping” or bend in the line is also seen in the picture recently published by De,5 and in other papers.2,4

That this complication occurs almost exclusively on the left1 has been attributed to the unique anatomy of the left ilio-femoral vein compared to the right.1 We believe that the local anatomy of the left ilio-femoral vein may also explain why the line loops when inadvertently entering the left ascending lumbar vein (fig 3). One can appreciate that, when the ascending lumbar vein is seen on the lateral1 and lateral-oblique view,1 and compared with the anterior posterior view, the vein can be seen to descend into the pelvis and then enter the ascending lumbar vein at an angle. On an x-ray the line will then project a loop or bend.

Another factor that may contribute to the appearance of the loop or bend is that it is probably difficult to advance the line up the narrow ascending lumbar vein, and therefore when trying to thread the line to its calculated length the line will “buckle” at this point.

Any loop or bend of a contrast filled line in the left ilio-femoral region should be regarded as a sign that the line has entered the ascending lumbar vein and pull the line back because the lumbar venous plexus will not always be visualised with contrast. There are serious complications of an unrecognised malpositioned long line.6 We feel that awareness of this radiological sign would facilitate early recognition and would prevent serious morbidity.

Changing incidence of respiratory presentations in primary care fact or artefact?

Recently reported declines in asthma morbidity1 may be difficult to interpret as they could reflect not only changes in incidence, but also changing disease severity, patient expectations, healthcare provision, and efficacy of pharmacological management. Indeed, it has been suggested that general practitioners may choose differing diagnostic labels for respiratory disease to justify prescribing medication.7

In view of these apparent inconsistencies, we used 37 practices taking part in the Scottish Continuous Morbidity Recording project (CMR) to determine possible changes in diagnostic fashion. Changes in the yearly age specific incidence (per 1000 population) were ascertained for the recording of diagnoses and symptoms including asthma, wheeze, and other respiratory illnesses including acute bronchitis, bronchiolitis, lower respiratory tract infection (LRTI), cough, chest infection, and acute respiratory infections combined (Read codes (version 2) used listed in table 1). The CMR project’s data collection processes have been described previously.3 Two child age groups were defined, namely those aged under 5 years of age (n = 12 693 children) and those aged 5-14 years (n = 30 165 children). Trends of disease incidence for six 12-month periods starting 31 March 1996 and ending 31 March

References

67

Changing incidence of respiratory presentations in primary care fact or artefact?

Recently reported declines in asthma morbidity1 may be difficult to interpret as they could reflect not only changes in incidence, but also changing disease severity, patient expectations, healthcare provision, and efficacy of pharmacological management. Indeed, it has been suggested that general practitioners may choose differing diagnostic labels for respiratory disease to justify prescribing medication.7

In view of these apparent inconsistencies, we used 37 practices taking part in the Scottish Continuous Morbidity Recording project (CMR) to determine possible changes in diagnostic fashion. Changes in the yearly age specific incidence (per 1000 population) were ascertained for the recording of diagnoses and symptoms including asthma, wheeze, and other respiratory illnesses including acute bronchitis, bronchiolitis, lower respiratory tract infection (LRTI), cough, chest infection, and acute respiratory infections combined (Read codes (version 2) used listed in table 1). The CMR project’s data collection processes have been described previously.3 Two child age groups were defined, namely those aged under 5 years of age (n = 12 693 children) and those aged 5-14 years (n = 30 165 children). Trends of disease incidence for six 12-month periods starting 31 March 1996 and ending 31 March

References

Acute bronchitis: H06.0 and below
Acute respiratory infections: H0 and below
Asthma: H33 and below
Bronchiolitis: H61 and below
Chest infection: H06.0 and below
Croup: H04.0
Lower respiratory tract infection: H62.1
Wheeze: 1737, R06.09

Table 1: Annual incidence of asthma and wheeze and lower respiratory disease

<table>
<thead>
<tr>
<th>Respiratory disease</th>
<th>Read code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>H33 and below</td>
</tr>
<tr>
<td>Acute bronchitis</td>
<td>H06.0 and below</td>
</tr>
<tr>
<td>Acute respiratory infections</td>
<td>H0 and below</td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td>H61 and below</td>
</tr>
<tr>
<td>Chest infection</td>
<td>H06.0 and below</td>
</tr>
<tr>
<td>Croup</td>
<td>H04.0</td>
</tr>
<tr>
<td>Lower respiratory tract</td>
<td>H62.1</td>
</tr>
<tr>
<td>Wheeze</td>
<td>1737, R06.09</td>
</tr>
</tbody>
</table>

2002 were tested for linear association using the Mantel-Haenszel χ² test, giving p for trend using Epi Info version 6.0 (Centers for Disease Control and Prevention, Atlanta, Georgia, USA). The study protocol was approved by the Scientific Advisory Group of the Primary Care Clinical Informatics Unit–Research, which is the registered guar-
dian for these anonymised data.

In the younger age group, there was a declining trend in the incidence of asthma (p < 0.001), with the rate of wheeze inci-
dence more than doubling over the study period. There was a small increase over the study period in the number of patients presenting with both asthma and wheeze (n = 16). Increases in the six year study period were observed for all other diseases considered as an alternative diagnosis for asthma (diagnostic transfer) (p < 0.001).

Overall, there was an increase in incidence rates for those recorded as having any one study disease or symptom (p < 0.001). Similar trends for asthma and wheeze were found for children aged 5–14 years.

In the present study, physician diagnostic labelling has been shown to change with time. There was a clear reduction in the labelling of the incident cases of asthma and evidence was also found for an increase in other diseases and symptoms that could be used as alternative diagnostic labels for asthma. Although these changes may have been influenced by British asthma guidelines published in 1997, which reiterated the importance of a correct diagnosis, changes in computer coding procedures should not have occurred, as a standard Read code dictionary was used by trained CMR practice data operators throughout the study period. These trends may have implications for large scale population surveys or studies that utilise data collected from routine clinical activity, leading to the accidental reporting of artefact.

Acknowledgements

C R Simpson, A J Lee, M W Taylor
Department of General Practice & Primary Care, The University of Aberdeen, Scotland, UK

P J Helms
Department of Child Health, University of Aberdeen, Scotland, UK

Correspondence to: Dr C R Simpson, Department of General Practice & Primary Care, Foresthill Health Centre, Westburn Road, The University of Aberdeen, Aberdeen AB25 2AY, Scotland, UK; c.simp@abdn.ac.uk
doi: 10.1136/adc.2004.063834

Competing interests: Peter J Helms has performed consultancies for Glaxo-Wellcome, Astra-Zeneca, and Merck Sharp & Dohme. Michael Taylor, Amanda Lee, and Colin Simpson have no competing interests.

References


Patient choice in medicine taking: religious sensitivities must be respected

Children often do not have choice in medicine taking, as it is typically their parents who agree, on their behalf, to receive prescribed treatments. Exploring parents’ and wherever possible also children’s beliefs about choice of medication is however important, particularly so when strong religious beliefs about treatment occur. The authors are grateful to the general practitioners who provided practice data to the Primary Care Clinical Informatics Unit–Research.


Patient choice in medicine taking: religious sensitivities must be respected

Children often do not have choice in medicine taking, as it is typically their parents who agree, on their behalf, to receive prescribed treatments. Exploring parents’ and wherever possible also children’s beliefs about choice of medication is however important, particularly so when strong religious beliefs about treatment occur. The authors are grateful to the general practitioners who provided practice data to the Primary Care Clinical Informatics Unit–Research.


Table 1  Examples of bovine, pork, and blood derived medications and possible alternatives

<table>
<thead>
<tr>
<th>Blood, bovine, and pork derived medications (generic and proprietary names)</th>
<th>Alternative preparations (generic and proprietary names)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>Crystalloidal e. g. saline</td>
</tr>
<tr>
<td>Human albumin Factor VIII</td>
<td>Recombinant factor VIII</td>
</tr>
<tr>
<td>Bovine</td>
<td>Amoxicillin (Amoxil) capsules</td>
</tr>
<tr>
<td></td>
<td>Omeprazole (Losec)</td>
</tr>
<tr>
<td>Pork</td>
<td>Pancreatin (Pancrease)</td>
</tr>
<tr>
<td>Portant alpha (Curosurf) MMR vaccine (MMR-II)</td>
<td>Colfasciner palmitate (Exasurf) MMR vaccine (Priorix)</td>
</tr>
<tr>
<td>Heparin calcium (Calcioparine)</td>
<td>Heparin (Arixtra)</td>
</tr>
<tr>
<td>Isoprophamide insulin (Hypurin)</td>
<td>Isophane insulin (Human insulin)</td>
</tr>
</tbody>
</table>

A pragmatic way of ensuring that health professionals have sufficient information about treatment options available would be for the British National Formulary to clearly indicate which preparations contain blood, animal, and alcohol derivatives, and, where possible, suggest suitable alternatives. The proposed electronic health records will facilitate the seamless sharing of patient information between healthcare providers. This will therefore offer an additional systematic approach for routinely collecting information, and through use of “prescribing alerts” can help inform clinicians about patient preferences in relation to medications.

But beliefs need to be balanced against clinical need. Recognising that many religious traditions offer a degree of relaxation of the respective laws in extenuating circumstances, there may be a need to work pragmatically with faith leaders to find acceptable compromises in cases where suitable treatments or treatment regimens do not exist, for example in the case of pancreatic preparations, which are all porcine origin (table 1).

Stereotyping must however be avoided. Arguably, even more important than knowledge of the main tenets of different faiths and access to information about the constituents of medicines then, is that prescribers have the skills and attitudes to explore and access to information about the main tenets of different faiths and awareness of parent’s religious sensitiveness so that these can be considered when prescribing (table 1). Jehovah’s Witnesses, for example, may choose to avoid blood derived products. Jewish law forbids any oral use of medication containing glycerol, stearates, lactose, and porcine products. Similarly, Hindus and Sikhs may be offended by medication containing animal products, particularly bovine derived products (for example, gelatine containing capsules). Islamic rulings that prohibit any systemic ingestion of pork or alcohol also need to be considered in the context of prescribing decisions involving Muslims.

Competing interests: ARG and AS have (voluntary) positions with the Research and Documentation Committee of Muslim Council of Britain. They, together with GM, were involved in the production of informed choice in medicine taking: drugs of porcine origin and clinical alternatives which was supported by an unrestricted educational grant from Sanofi-Synthelabo. Lord Hunt is Chairman of the National Patient Safety Agency.

References


Lessons from an unsuccessful local attempt to tackle childhood overweight and obesity

While we greatly enjoyed Mary C J Rudolph’s “Best Practice” article on “The Obese Child”, we cannot agree with her conclusion that obesity fulfils most of the criteria for a condition that justifies screening. Our own local experience in Solihull, West Midlands, might illustrate this point.

Using a grant from the Children’s Fund (www.cypu.gov.uk/corporate/childrentrust/index.cfm) we aimed to set up a “Fit Club” serving children aged 7–11 in seven wards in Solihull, with DETRI deprivation indices ranging from 7.53 to 54.49. All seven wards contain enumeration districts with deprivation indices in the worst 15% of the country.

We attempted to recruit 20 children, for an initial consultation phase, in which they and their families would be able to discuss with our multidisciplinary team the kinds of services they would like to take the child’s weight. They would be able to try out various exercise programmes if they wished, as well as receiving dietetic advice, and as an incentive we also offered £10.00 worth of fresh fruit and vegetables. The only criterion for recruitment was that the child should be perceived to have a weight problem both by their family and professionals.

We attempted to recruit children via contact with school nurses, recommendation from general practitioners, and an advertisement in the local paper. To our disappointment, we found that we were able to recruit only four children. GPs had forwarded seven names, of whom one actually made contact with the service, while the school nurses informally fed back that families felt that their child’s weight was not an issue on which they needed to take action. A final attempt at recruitment, based on one large primary school with support of teaching staff, was similarly completely unsuccessful. It would seem likely that a difference in perception of the seriousness of overweight and the need for action between parents and professionals explained our disappointing outcomes.

Our experience thus leads us to believe that detecting obese or overweight children by screening will not substantially alter the scale of these problems on a population basis, although services for those that do request them are clearly justified.

N Haisman, K A Matyka, A Stanton
Solihull Primary Care Trust, West Midlands, UK; haismann@hotmail.com

Author’s reply

Drs Haisman, Matyka, and Stanton describe their disappointing and frustrating experience of offering a programme for obese children. However this experience cannot be used to argue that screening would have no value.

My comment that obesity fulfils most of the criteria for screening was based on the fact that: it is a common condition with serious consequences; it can be identified in its early stages; and it is potentially reversible. If it was reversed the costs of identifying obese children would be more than offset by the savings in health care later. The big “but” is the one (and very major) problem that we cannot offer effective treatment. If we can resolve that, then undoubtedly we should be screening our school age population.

The Solihull experience is not universal. With current sympathetic media interest the climate is changing and we are finding that...
families are seeking help. Our WATCH IT community based programme in Leeds has 65 children enrolled with good attendance and we now have a waiting list.

Rather than dismiss the idea of screening at some point in the future, let us argue for more resources to develop clinically effective interventions.

M C J Rudolf
Department of Community Paediatrics, Belmont House, 3–5 Belmont Grove, Leeds LS17 8DR, UK.
mary.rudolf@leedsth.nhs.uk

Patterns and risks in spinal trauma: the emergency transport perspective

The article by Martin and colleagues’ reviewing patterns and risks in spinal trauma highlights the increased incidence of spinal cord injury (SCI) and spinal cord injury without radiological abnormality (SCIWORA) in young children. They suggest that without clinical suspicion proper evaluation of the child’s spine may not occur, and refer to an audit by Skellet and colleagues’ that shows inadequate spinal immobilisation of paediatric trauma patients on arrival of the paediatric retrieval team.

Preventing secondary injury during transfer (movement of patients between hard surfaces in close proximity) and transport (patient movement between facilities) is particularly important. There are a number of devices available to facilitate spinal immobilisation during transfer and transport. These include spinal board (SB), vacuum mattress (VM), patslide, and scoop device in combination with traditional hard collar, blocks, and tapes to provide cervical spine immobilisation.

We carried out a survey to identify the current practices in immobilisation, transfer, and transport of the paediatric trauma patient with actual or potential SCI. Postal questionnaires were sent to the retrieval coordinators in 18 UK paediatric ICUs asking about methods of spinal immobilisation during transfer and transport of paediatric trauma patients and existence of guidelines for management of that population. There was a 100% response rate (postal plus follow up phone calls to two centres). Only 27% (5/18) of retrieval services employed practice guidelines. For patient transfer, 27% (5/18) of retrieval services utilised a patslide device alone and 50% (9/18) utilised a patslide in combination with a vacuum mattress and/or spinal board (table 1). For patient transport, 67% (12/18) of services had a consistent approach (table 2). A spinal board, either alone or with padding, was used by 72% (13/18) of services for at least some of their patient transports.

One hundred per cent of services used the traditional triad of hard collar, sandbags/blocks, and tape/straps for maintaining cervical spine immobilisation. As Martin et al have described, SCI and SCIWORA occur more frequently in younger children. Without an obvious radiological abnormality, these injuries may potentially be overlooked. Prevention of secondary injury is thus important during transport of at risk patients. Our survey illustrates that there is a lack of a consistent approach to spinal immobilisation during transfer and transport of paediatric trauma patients. There is also continuing use of spinal boards despite evidence that they should only play a role during extrication of patients in the pre-hospital setting’ and that vacuum mattresses may confer benefits in terms of patient safety and comfort.

The development of best practice guidelines may lead to a more consistent approach.

S A Russ, S W H Hancock, M Quinton, R Moore
Sheffield Children’s Hospital, UK

P Harrison
Princess Royal Spinal Injuries Unit, Sheffield, UK

Correspondence to: Dr S W H Hancock, Consultant Paediatric Intensivist, Sheffield Children’s Hospital Retrieval Service, UK; stephen.hancock@sch.nhs.uk
doi: 10.1136/adc.2005.072546

Competing interests: none declared

References

Dapsone therapy for Henoch-Schönlein purpura: a case series

Henoch-Schönlein purpura (HSP), first recognised by Heberden in 1801, is a systemic, IgA mediated vasculitis of small vessels that is usually self-limiting but may progress to gastrointestinal bleeding, intussusception, and nephropathy. A third of patients will experience recurrences. Currently treatment is confined to rest, analgesia, and steroids for refractory abdominal pain, and immunosuppressants for complications, especially renal disease.

Original reports, predominantly in adults, show that the symptoms of purpuric rash, abdominal pain, and arthritis in HSP respond to treatment with dapsone.

Even though the first case of HSP treated with dapsone was reported in 1983, it is still not generally recognised as a treatment for HSP. We describe eight children in whom, because of the severity or persistence of their symptoms, treatment with dapsone was commenced from among 41 patients diagnosed with HSP from January 1992 to May 2004. All gained a clinical response from treatment with the most beneficial effect on the skin rash. The demographic characteristics of the patients and their presenting clinical features as well as treatment are shown in table 1. The rash improved within 3 days to 1 week of starting treatment with dapsone in all patients. Six of eight relapsed when treatment was stopped, but responded again to treatment. The side effects are dose related and uncommon at doses commonly used (1–2 mg/kg daily).

Dapsone, an antimalarial drug, used for a variety of dermatological conditions, appears to be of special value in diseases characterised by accumulation of neutrophils, notably with leucocytoclastic vasculitis, of which HSP is an example. There is evidence that it has anti-oxidant scavenger effects and may suppress the generation of toxic free radicals in neutrophils. It also inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. It may also inhibit IgA-neutrophil interactions. Given the pathogenesis of HSP with IgA mediated vasculitis, treatment with dapsone represents an exciting form of treatment. The clinical course of our patients suggests that dapsone controls the cutaneous vasculitis rather than cures it. As steroids may mask the features of more ominous intestinal disease, dapsone can be a reasonable alternative. Nonetheless, to date there is no evidence of a positive effect on renal disease.

In conclusion, dapsone is a drug that may have a role in the treatment of HSP. In order to establish its usefulness it is necessary to conduct a multicentre, placebo, randomised controlled trial.

Informed consent was obtained from parents before starting treatment with dapsone.

H Iqbal, A Evans
Queen Elizabeth Hospital, London, UK

Correspondence to: Dr H Iqbal, Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4JQ, UK; humai@tiscali.co.uk
doi: 10.1136/adc.2004.061598

Competing interests: none declared

References
If community paediatricians did not exist, it would be necessary to invent them

Since 1991 there has been talk of abolishing community paediatrics as a specialty.1 At that time, a group of related specialties was proposed: a specialty of child development and rehabilitation (neurodisability); child protection would be subsumed into general paediatrics and there would be child public health doctors. Since then there has been a view among some paediatricians that community paediatricians should become the general paediatricians of the future.2, 3 Dr Chambers’ recent article proposes a narrow view of community paediatrics, concentrating on chronic illness and confining its role to diagnosis and medical management.4 He rather misses the point.

The challenge of community paediatrics

Children do not come in neat packages, with diagnostic labels. They and their families need all their needs met. Hospital practice traditionally concentrates on the illness, not the patient, although this is becoming less with time and paediatricians have always been more holistic than adult counterparts. Hospital practice often deals with complex problems by having specialists for each problem. Our adult physician colleagues are beginning to realise that doesn’t work and are reinforcing the generalist viewpoint.

It has been shown that community paediatric patients have significantly more complex problems than those presenting to general paediatricians.5 Many of the conditions we diagnose and treat have no diagnostic tests. Community paediatricians need excellent clinical skills, must be able to manage complexity and uncertainty, and must have the ability to communicate across disciplines and across agencies, creating understanding in those who come from different backgrounds and with different agendas. It is not an easy job.

The National Service Framework

The NSF was constructed by multidisciplinary groups including parents. It is therefore no accident that child health, not illness, is emphasised. Hospital practice has rather less emphasis than crossingcutting “out of hospital” issues. Communication, coordination, and early intervention are all key themes. Parents and our sister agencies value medical input that is holistic, available where it is needed (not just in the clinic), and attuned to the needs of the child and family in the community. They demand more of it than we can currently give. Nevertheless, child health outside hospital has moved up the agenda and it will be hard for local authorities to deliver Every Child Matters without focused child health support to education, social, and voluntary services, as well as child health per se. This new agenda requires exactly the skills community paediatricians have. If community paediatricians did not exist, it would be necessary to invent them to deliver the NSF. The challenge is how we tackle it.

Dr C M Ni Bhrolchain
Consultant Community Paediatrician, Wirral Hospital NHS Trust, UK; cliona_nib@liveone.net

Competing interests: Dr Ni Bhrolchain in a Specialty Training Advisor in Community Child Health. These views are her own.

References

1 Hall DMB. Do we really need community paediatricians? A summary of the lecture given to the Triennial Meeting of the Scottish Paediatric Society. Eur J Pediatr 1991;150:530–1.


Melatonin: a panacea for desperate parents? (Hype or truth)

Sleep disorders are common in children with neurodevelopmental disorder and are a major source of stress for the whole family. In children with neurodevelopmental disabilities the prevalence may be as high as 80%.1 The current literature is suggestive of circadian rhythm dysfunction, social difficulties, and abnormal melatonin levels in children with autism.2 Hypnotics and sedatives can produce side effects and tolerance,3 so is melatonin the answer in children with sleep problems associated with severe developmental difficulties of social and communicating nature, which have not responded to behavioural and social measure? Previous studies and case reports have suggested that melatonin could be effective.

We retrospectively reviewed cases of nine autistic children with chronic sleep disorder, who were attending the Child Development Centre at Windmill Lodge. The age range of these children was 2–11 years. No additional non-pharmacological sleep intervention was instituted. They were started on 2.5–5 mg melatonin 45 minutes before their sleeping time. In four of these patients sleep latency was reduced. Our own experience of reduction in sleep latency is in accordance with literature.4 Five parents reported improvement in total duration of sleep. In

---

Table 1 Demographic characteristics, presenting clinical feature, and treatment of the patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at presentation</td>
<td>22 m</td>
<td>8 y</td>
<td>8 y</td>
<td>5 ½ y</td>
<td>10 y</td>
<td>5 y</td>
<td>8 y</td>
<td>10 y</td>
</tr>
<tr>
<td>Sex</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Race</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>Vietnamese</td>
<td>White</td>
</tr>
<tr>
<td>Presenting features</td>
<td>Miserable</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Diarrhoea</td>
<td>Pustules</td>
</tr>
<tr>
<td>Rash</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Joint pain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Vomiting</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Swollen testicles</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Haematuria</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Proteinsuria</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rectal bleeding</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Length of presentation</td>
<td>1 d</td>
<td>2 d</td>
<td>2 d</td>
<td>1 d</td>
<td>5 d</td>
<td>4 d</td>
<td>5 d</td>
<td>1 d</td>
</tr>
<tr>
<td>Presentation to</td>
<td>10 d</td>
<td>14 m</td>
<td>18 m</td>
<td>5 d</td>
<td>8 d</td>
<td>11 d</td>
<td>1 m</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>1 mg/kg od</td>
<td>1.3 mg/kg od</td>
<td>1 mg/kg od</td>
<td>1.25 mg/kg od</td>
<td>0.75 mg/kg bd</td>
<td>1 mg/kg od</td>
<td>1 mg/kg od</td>
<td>0.5 mg/kg bd</td>
</tr>
<tr>
<td>Length of first course</td>
<td>6 d</td>
<td>7 d</td>
<td>4 d</td>
<td>4 w</td>
<td>7 d</td>
<td>14 d</td>
<td>10 d</td>
<td></td>
</tr>
<tr>
<td>Positive response</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Relapse after first course</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Total duration of treatment</td>
<td>6 d</td>
<td>7 d</td>
<td>2 d</td>
<td>2½ y</td>
<td>8 m</td>
<td>5 w</td>
<td>5 w</td>
<td>2 y</td>
</tr>
</tbody>
</table>

An integrated care pathway for looked after children can facilitate multi-agency coordination

Looked after children are a vulnerable population at risk of unidentified and unmet health needs. Coordinated input from health, social care, and education services for these children is required by government but is not easily achieved.

The focus on looked after children has sharpened with the Quality Protects programme, a major initiative launched in 1998 to improve their life chances. In 2002, the Department of Health (DH) published guidelines for managing children with neurodevelopmental disorders in a generic manner. This will not furnish the answer as to the true place of melatonin in the management of disturbed sleep patterns.

References


An integrated care pathway (ICP) is a health sector concept that “determines locally agreed multidisciplinary practice based on guidelines and evidence, where available, for a specific patient user group. It forms all or part of the clinical record, documents the care given and facilitates the evaluation of outcomes for sustainable quality improvement.” The ICP concept is multifaceted and complex but consists of both a process (of development and continuing maintenance) and a set of operational products. It can usefully be extended as a tool to improve multi-agency working.

An ICP promotes the health of looked after children. The ICP does not prevent the symptoms, but it is a mechanism to enhance collaborative working across agencies for specific populations such as looked after children. An integrated care pathway (ICP) is a health sector concept that “determines locally agreed multidisciplinary practice based on guidelines and evidence, where available, for a specific patient user group. It forms all or part of the clinical record, documents the care given and facilitates the evaluation of outcomes for sustainable quality improvement.”

The Children Act 2004 sets out a new framework for children’s services with Directors of Children’s Service and Lead Members for children in each local authority. The government is establishing Children’s Trusts to direct the coordination and integration of planning, commissioning, and delivery of health, social care, and education services. How are these agencies to work together more effectively? There are well recognised facilitators and barriers to coordinating multi-agency practice. Poor communication between agencies and a lack of understanding of each other’s roles and responsibilities has been a barrier and is a recurring feature in reports of children and child deaths.

An integrated care pathway (ICP) is a health sector concept that “determines locally agreed multidisciplinary practice based on guidelines and evidence, where available, for a specific patient user group. It forms all or part of the clinical record, documents the care given and facilitates the evaluation of outcomes for sustainable quality improvement.”

The ICP concept is multifaceted and complex but consists of both a process (of development and continuing maintenance) and a set of operational products. It can usefully be extended as a tool to improve multi-agency working. An ICP promotes the health of looked after children. The ICP does not prevent the symptoms, but it is a mechanism to enhance collaborative working across agencies for specific populations such as looked after children.
A real and "live" feel. This DVD, with its many excellent clips showing physical examination, is the best thing to examining the child yourself, certainly better than a didactic session. The module on holding an immunisation clinic was a profound experience which made me think about the practical aspects of delivering effective immunisation. The module can be found online in the "Green module" and its updates at http://www.immunisationinpractice.org. This book aims to provide a resource of concise advice and certainly fulfil the role of a revision text. However, we would like to have seen cardiac tamponade included as a cause, and more up to date teaching on this subject. The authors have decided to remove the practical sections on the use of echocardiography in the list of investigations to exclude this. The session on maternal HIV infection was underused vaccines such as Hib, yellow fever, meningococcal B. The second edition of the book is divided into eight modules with summary tables to emphasise key points and references. The first clinical scenario was a baby whose mother was diagnosed with maternal HIV infection. We decided to do a test run using the book and we were disappointed as there was no mention of the use of blood products in their clinical management. The authors re-addressed many of the new vaccines used in the UK, for example, conjugated pneumococcal or meningococcal vaccines, for example, DTP-HepB conjugate. We were also slightly disappointed as there was no mention of a formula anywhere. The second scenario was the counselling of a couple who were regular attendees at the antenatal clinic and had just found out that the father had type 1 diabetes. The authors have decided to use the word "conjugated jaundice" in the book, and we were disappointed as there was no mention of a formula anywhere. The third scenario was the counselling of a twin whose mother had uncontrolled epilepsy and had just been diagnosed with congenital syphilis. The authors have decided to introduce some new vaccines into the book, and we were disappointed as there was no mention of a formula anywhere. The fourth scenario was the family of a 1 year old baby. The authors have decided to use the word "continuous positive airway pressure" in the book, and we were disappointed as there was no mention of a formula anywhere. The fifth scenario was the family of a 6 month old baby. The authors have decided to use the word "injection" in the book, and we were disappointed as there was no mention of a formula anywhere. The sixth scenario was the family of a 2 month old baby. The authors have decided to use the word "intracranial haemorrhage" in the book, and we were disappointed as there was no mention of a formula anywhere. The seventh scenario was the family of a 1 month old baby. The authors have decided to use the word "physician" in the book, and we were disappointed as there was no mention of a formula anywhere. The eighth scenario was the family of a newborn baby. The authors have decided to use the word "physician" in the book, and we were disappointed as there was no mention of a formula anywhere.
lymphohistiocytosis and ARC syndrome made us acutely aware that the book is from Birmingham!

In summary, this book would be a useful edition to neonatal units as a rapid reference guide, particularly for the excellent web links. The layout of the book is very practical and in a problem oriented style. The lists given under “aetiology” of most conditions are extensive and theoretical, but will be a helpful revision aid for junior doctors and nurses.

S Thayyil, A L Ogilvy-Stuart

Prevention of allergy and allergic asthma: World Allergy Organization project report and guidelines


Edited by two Scandinavian experts in the field, this book is the result of a working group of the World Allergy Organization (WAO) and the WHO. With contributions by authors from 21 countries it presents a contemporary international overview and consensus of what is known and not known about prevention (primary, secondary, and tertiary) of allergic disorders.

The introduction includes clear definitions of some terms such as allergy and hypersensitivity. It also sets out the useful instruction to all the authors to include an evidence base category with all references—and this book cannot be criticised for a lack of references.

The genetics of allergy are then reviewed in detail that is moderately technical but highlights some of the problems with the results from research to date, such as the varying definitions of atopy (that is, phenotype definition) used in different studies. Despite much effort and the advance of molecular biology, there are still few new certainties about the inheritance of allergy, but strategies for future work are described.

Unsurprisingly, the longest chapter in the book analyses proposed environmental influences causing asthma and allergy. Various dietary factors from fish oils to food additives are discussed. Topical issues such as the hygiene hypothesis, the influence of immunisations, antibiotics, and probiotics (live microbial food components) are all examined and the data presented concisely. What is known about the benefits of breast feeding and weaning is also summarised. The clearest conclusion is that environmental tobacco smoke is bad for allergic airways disease and more governmental action is required.

Another chapter reviews the fascinating issue of immunological influences on the fetus and neonate, showing that significant immune responses occur in utero, influenced by passage of allergen from mother to fetus. Subsequently, the interventions in infants at high risk of developing allergy are concisely analysed with regard to altering maternal diet during pregnancy and lactation and reducing household aeroallergens. Of clinical relevance is the conclusion that there is no evidence of a preventative benefit of soy based compared with cows’ milk formulae.

“Can I do anything to stop my child getting asthma and/or eczema” is a concern of an increasing number of parents. Paediatricians, who are often faced with this question, do not have easy access to specialist allergy opinion at present, because allergy as a medical speciality in the UK could itself be considered to suffer from “failure to thrive”. Any paediatrician or clinician with an interest in asthma, eczema, or food allergy (are there any who don’t?) will find this book helpful. For anyone drafting local ward and/or community guidelines for nutrition, weaning, and allergy, it provides an evidence base and also some suggested information sheets and guidelines.

A minor criticism is that the subject index suffers from restricted development. In conclusion, this book would be a useful resource for those interested in allergy within specialist departments and also for reference to the general paediatrician with an interest.

I Pollock

CORRECTION

doi: 10.1136/adc.2003.032052corr1

Kendrick D, Royal S. Cycle helmet ownership and use; a cluster randomised controlled trial in primary school children in deprived areas (Arch Dis Child 2004;89:330–5). There were two errors in the sample size calculation for this article. The correct figures should be 93% (not 90% in the calculation for helmet ownership) and 44.5% (not 44.5% in the calculation for helmet wearing). Therefore, the sample size calculation should read:

The study had 80% power to detect a difference in the percentage of children owning a helmet from 81% to 93% between the 2 treatment groups.

and

It had 80% power to detect a difference in the percentage of children always wearing a helmet from 34% to 48.5%, at the 5% significance level.